Skip to content Skip to footer
Subscribe Now
Mitigating Cardiovascular Therapy Gaps: Saif Rathore and Andrew Epstein in a Riveting Conversation with PharmaShots
VIEWPOINTS

Mitigating Cardiovascular Therapy Gaps: Saif Rathore and Andrew Epstein in a Riveting Conversation with PharmaShots

Shots: Did you know that coronary stent usage can decline by 20 percent if GLP-1 therapy is used as widely as statin therapy? PharmaShots welcomes Saif Rathore, Founder of Sandbar Life Sciences and Entrepreneur-in-Residence at Yale Ventures, and Andrew Epstein, Principal at Medicus Economics, for an illuminating dialogue exchange Saif and Andrew highlight the untapped…
June 4, 2025

Read more

Takeda at ASH 2024: Phuong Khanh Morrow from Takeda in a Riveting Conversation with PharmaShots
VIEWPOINTS

Takeda at ASH 2024: Phuong Khanh Morrow from Takeda in a Riveting Conversation with PharmaShots

Shots: Recently, at ASH 2024, Takeda presented data from several ongoing clinical trials across hematology and oncology, including the Phase II OPTIC and Phase III PhALLCON studies, among others Phuong Khanh Morrow, Head of the Oncology Therapeutic Area Unit at Takeda, shed light on Takeda’s key presentations at ASH 2024 Phuong also highlighted the findings…
June 2, 2025

Read more

Chronic Dermatologic Care: Baldo Scassellati Sforzolini from Galderma in Conversation with PharmaShots
VIEWPOINTS

Chronic Dermatologic Care: Baldo Scassellati Sforzolini from Galderma in Conversation with PharmaShots

Shots: Recently, the groundbreaking results from Galderma’s Phase III OLYMPIA 1 trial were published in JAMA Dermatology. The study evaluated nemolizumab in patients with moderate-to-severe active prurigo nodularis The trial met all primary and secondary endpoints, with results aligning with those from the OLYMPIA 2 trial, reinforcing nemolizumab’s potential in achieving sustained improvements in the…
May 26, 2025

Read more

Infusing Automation: Suresh Kannan from Model N in an Illuminating Discussion with PharmaShots
VIEWPOINTS

Infusing Automation: Suresh Kannan from Model N in an Illuminating Discussion with PharmaShots

Shots: Identifying discrepancies remains a key challenge for manufacturers in mitigating revenue leakage and ensuring alignment with payer plans Suresh Kannan, Model N’s Chief Product Officer, offers insights into the newly launched GenAI and enhanced data solutions aimed at optimizing revenue and ensuring compliance He also outlines a strategic approach to formulary identification and emphasizes…
May 21, 2025

Read more

Advancing Lupus Research: Devon Kelly from Lupus Nexus in a Stimulating Conversation with PharmaShots
VIEWPOINTS

Advancing Lupus Research: Devon Kelly from Lupus Nexus in a Stimulating Conversation with PharmaShots

Shots: Research into Lupus has yielded groundbreaking results in pharmacokinetics and pharmacodynamics, yet experts still don't understand its cause Lupus Research Alliance (LRA) recently launched a platform called Data Repository, Exchange, and Analytics (DREAM) for data sharing and partnerships for research in lupus Devon Kelly, Director of Lupus Nexus at the Lupus Research Alliance, sheds…
May 19, 2025

Read more

Hlth
EVENTS

2025 | HLTH Europe: 16-19 June | Amsterdam

HLTH Europe is the continent’s #1 healthcare innovation event. Following an enormously successful first event in 2024 and the exponential growth of HLTH in the US, this landmark event is where global expertise meets local insight to address Europe's unique healthcare challenges and opportunities.Don’t miss out on this opportunity to connect with like-minded individuals…
May 6, 2025

Read more

Takeda at AASLD 2024: Chinwe Ukomadu in a Riveting Dialogue Exchange with PharmaShots
VIEWPOINTS

Takeda at AASLD 2024: Chinwe Ukomadu in a Riveting Dialogue Exchange with PharmaShots

Shots:  AATD-associated liver disease is a progressive genetic disorder with no approved therapy, and liver transplantation remains the only option for patients with end-stage disease. Fazirsiran is an investigational RNAi therapy designed to treat AATD-associated liver disease by lowering the production of Z-AAT. PharmaShots welcomes Dr. Chinwe Ukomadu, Head of the Gastrointestinal and Inflammation Therapeutic…
May 5, 2025

Read more

Viewpoints_Jesse Mendelsohn
VIEWPOINTS

Predicting 2025 Trends: Jesse Mendelsohn from Model N in an Illuminating Discussion with PharmaShots

Shots: Several undulating factors coalesce to inadvertently shape the biopharma industry Prominent challenges include mounting pressure on Pharmacy Benefit Managers from independent pharmacies and drug manufacturers, a growing shortage of GLP-1 drugs, and the addition of 15 more drugs to the Inflation Reduction Act’s price negotiation list. Jesse Mendelsohn, SVP at Model N, emphasizes the…
April 28, 2025

Read more

Thoughtspot_Saurabh_Chaubey
THOUGHTSPOT

Personalized Medicine: A Paradigm Shift in Modern Treatment Approach

Shots:  Precision medicine holds a promising foothold in addressing unmet healthcare needs and bridging the gaps in care accessibility and high treatment costs Defying the one-size-fits-all model, personalized medicine offers therapies tailored to an individual’s physiology, lifestyle, and environment With this article, let’s capture the intricacies of precision medicine by navigating the benefits, challenges, progress,…
April 23, 2025

Read more

Viewpoints_Vijay Nadipelli
VIEWPOINTS

Evaluating SDoH in SLE: Vijay Nadipelli from GSK in a Riveting Conversation with PharmaShots

Shots: SDoH screening can help identify patient needs, support faster clinical decisions, and improve patient-centric care A first-of-its-kind lupus study surveyed 69 patients across two institutions to assess the feasibility of routine SDoH screening in lupus clinics and identify related barriers and enablers at the physician, care team, and patient levels Vijay Nadipelli, Senior Director…
April 21, 2025

Read more

Load more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]